← Ticker index
INCY
Ticker
INCY
Congressional Trades
24
by 2 members
Ticker disclosure brief
Congressional disclosure records for INCY
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
BUY · 2026-05-15
Largest range
$1K – $15K
Ro Khanna
Longest observed gap
35d
Ro Khanna
Highest 30d vs SPY
73.0%
Ro Khanna
Purchase rows
15
63%
Sale rows
9
38%
Disclosed midpoint
$192K
range estimate
Unique Traders
2
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats21 · 88%
Republicans3 · 13%
Federal awards
all →- 2026-03-27$500KDepartment of Veterans AffairsPATHOLOGY LAB SERVICES.
Lobbying filings
all →- 2026-07-05$50KINCYTE CORPORATIONHealthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.
- 2026-04-20$480KINCYTE CORPORATIONH.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
- 2026-04-20$60KINCYTE CORPORATIONIssues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to CMMI demos (Guarding U.S. Medicare Against Rising Drug Costs (GUARD) and Global Benchmark for Efficient Drug Pricing (GLOBE))
- 2026-04-18$80KINCYTE CORPORATIONIssues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
- 2026-04-18$60KINCYTE CORPORATIONEducation around access to innovative therapies in dermatology. Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing.
- 2026-04-17$110KINCYTE CORPORATIONIssues relating to CMS coverage and reimbursement policies.
- 2026-04-17$50KINCYTE CORPORATIONHealthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.
- 2026-01-20$530KINCYTE CORPORATIONH.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
- 2026-01-20$80KINCYTE CORPORATIONIssues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
- 2026-01-20$70KINCYTE CORPORATIONIssues relating to CMS coverage and reimbursement policies.
Loading trade analytics…
All Disclosed Trades
Page 1 · 24 of 24 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2026-05-15 | DRo Khanna | BUY | $1K – $15K | 25d | receipt → |
| 2026-03-30 | DRo Khanna | BUY | $1K – $15K | 8d | receipt → |
| 2026-03-10 | DRo Khanna | SELL | $1K – $15K | 28d | receipt → |
| 2026-03-10 | DRo Khanna | SELL | $1K – $15K | 28d | receipt → |
| 2026-03-30 | DRo Khanna | BUY | $1K – $15K | 8d | receipt → |
| 2026-01-29 | DRo Khanna | BUY | $1K – $15K | 8d | receipt → |
| 2026-01-29 | DRo Khanna | BUY | $1K – $15K | 8d | receipt → |
| 2025-05-19 | DRo Khanna | BUY | $1K – $15K | 22d | receipt → |
| 2025-05-19 | DRo Khanna | BUY | $1K – $15K | 22d | receipt → |
| 2025-05-15 | RRobert Bresnahan | SELL | $1K – $15K | 18d | receipt → |
| 2025-05-15 | RRobert Bresnahan | SELL | $1K – $15K | 16d | receipt → |
| 2025-05-15 | RRobert Bresnahan | SELL | $1K – $15K | 16d | receipt → |
| 2025-02-19 | DRo Khanna | SELL | $1K – $15K | 15d | receipt → |
| 2025-02-19 | DRo Khanna | SELL | $1K – $15K | 15d | receipt → |
| 2025-01-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2025-01-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-11-15 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-11-15 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-08-02 | DRo Khanna | BUY | $1K – $15K | 35d | receipt → |
| 2024-08-02 | DRo Khanna | BUY | $1K – $15K | 35d | receipt → |
| 2024-04-23 | DRo Khanna | SELL | $1K – $15K | 13d | receipt → |
| 2024-04-23 | DRo Khanna | SELL | $1K – $15K | 13d | receipt → |
| 2024-03-25 | DRo Khanna | BUY | $1K – $15K | 11d | receipt → |
| 2024-03-25 | DRo Khanna | BUY | $1K – $15K | 11d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.